“…The vasoconstrictor effect of ET-1 has been implicated in the cerebrovascular dysfunction occurring in stroke, subarachnoid hemorrhage, chronic intermittent hypoxia, and brain trauma (1,5,9,11,18,23,26,27,31). It is generally accepted that the mechanisms of vasoconstrictor effects of ET-1 involves smooth muscle ET A receptors that initiate phosphorylation-dependent signaling, including PKC, MAPK, and phosphatidylinositol 3-kinase/PKB pathways, and also Ca 2ϩ -dependent activation of calmodulin and myosin light chain kinase (4,9,29,31,33,35).…”